
## Aloysius Ho

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7803182/publications.pdf Version: 2024-02-01



Διονείμε Ηο

#	Article	IF	CITATIONS
1	One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica, 2022, 107, 1045-1053.	1.7	87
2	Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party. Bone Marrow Transplantation, 2020, 55, 1050-1058.	1.3	42
3	Mobilization kinetics of peripheral blood stem cells with rescue plerixafor – real-world experience from a single center. Leukemia and Lymphoma, 2020, 61, 1740-1743.	0.6	0
4	Donorâ€ŧype fresh frozen plasma is effective in preventing hemolytic reaction in major ABO incompatible allogeneic stem cell transplant. Transfusion, 2019, 59, 335-339.	0.8	6
5	Asthmatic adult with marked blood eosinophilia: is it truly asthma?. BMJ Case Reports, 2018, 2018, bcr-2017-222344.	0.2	2
6	Longâ€ŧerm renal outcome after allogeneic hemopoietic stem cell transplant: A comprehensive analysis of risk factors in an Asian patient population. Clinical Transplantation, 2017, 31, e12920.	0.8	4
7	Respiratory virus infection after allogeneic hematopoietic stem cell transplant in a tropical center: Predictive value of the immunodeficiency scoring index. Transplant Infectious Disease, 2017, 19, e12693.	0.7	18
8	Long-Term Outcomes of Alemtuzumab-Based Reduced-Intensity Conditioned Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Secondary to Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2014, 20, 111-117.	2.0	27
9	Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML. Bone Marrow Transplantation, 2010, 45, 633-639.	1.3	47
10	Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. British Journal of Haematology, 2008, 141, 235-243.	1.2	44
11	Eczematoid Graft-vs-Host Disease. Archives of Dermatology, 2007, 143, 1157-62.	1.7	55
12	Clonal gammopathies following alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation: association with chronic graft-versus-host disease and improved overall survival. Bone Marrow Transplantation, 2007, 40, 747-752.	1.3	15
13	CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia, 2007, 21, 1937-1944.	3.3	147
14	Sclerodermatous graft-versus-host disease: clinical spectrum and therapeutic challenges. British Journal of Dermatology, 2007, 156, 1032-1038.	1.4	44
15	Complete response of deep neutrophilic dermatosis associated with myelodysplastic syndrome to 5-azacytidine. British Journal of Dermatology, 2007, 156, 1039-1041.	1.4	15
16	Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. British Journal of Haematology, 2007, 137, 374-375.	1.2	38
17	Outcomes of MDS Patients with Chromosome 7 Abnormalities Treated with 5-Azacytidine Blood, 2007, 110, 1449-1449.	0.6	4
18	Fanconi-Like Syndrome with Negative Chromosomal Breakages Test and High Incidence of Myelodysplasia Blood, 2007, 110, 1681-1681.	0.6	9

ALOYSIUS HO

#	Article	IF	CITATIONS
19	Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood, 2006, 108, 2928-2936.	0.6	129
20	Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT). Bone Marrow Transplantation, 2006, 38, 823-824.	1.3	26
21	An immune edited tumour versus a tumour edited immune system: prospects for immune therapy of acute myeloid leukaemia. Cancer Immunology, Immunotherapy, 2006, 55, 1017-1024.	2.0	31
22	Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. Journal of Medical Virology, 2006, 78, 1560-1563.	2.5	48
23	Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2005, 35, 299-301.	1.3	42
24	Isochromosome of a deleted 20q: a rare but recurrent chromosome abnormality in myelodysplastic syndromes. Cancer Genetics and Cytogenetics, 2005, 156, 154-157.	1.0	21
25	Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation Is as Effective in Poor Risk as Standard Risk Acute Myeloid Leukaemia (AML) Blood, 2005, 106, 2901-2901.	0.6	0
26	Improved Disease Free Survival Following Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation Incorporating Alemtuzumab Compared with Autologous Stem Cell Transplantation in Follicular Lymphoma Blood, 2005, 106, 1144-1144.	0.6	0
27	BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood, 2004, 103, 428-434.	0.6	171
28	Single Centre Experience of Patients with Haematological Malignancies Admitted to Intensive Care Unit: A Comparative Review of Allogenic Bone Marrow Transplant Data Blood, 2004, 104, 1830-1830.	0.6	0
29	Reduced-intensity allogeneic hematopoietic stem cell transplantation with alemtuzumab conditioning regimens: survival does not plateau until after day 200 Blood 2003 101 779-780	0.6	9